These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31778110)

  • 41. The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development.
    Preston A
    Hum Vaccin Immunother; 2016 May; 12(5):1274-6. PubMed ID: 26889694
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pertactin-deficient Bordetella pertussis isolates in Poland-a country with whole-cell pertussis primary vaccination.
    Polak M; Zasada AA; Mosiej E; Krysztopa-Grzybowska K; Witkowski L; Rzeczkowska M; Piekarska K; Lutyńska A
    Microbes Infect; 2019; 21(3-4):170-175. PubMed ID: 30580013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation.
    Mielcarek N; Debrie AS; Raze D; Quatannens J; Engle J; Goldman WE; Locht C
    Vaccine; 2006 Apr; 24 Suppl 2():S2-54-5. PubMed ID: 16823926
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
    Barkoff AM; Guiso N; Guillot S; Xing D; Markey K; Berbers G; Mertsola J; He Q
    J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Cellular and acellular anti-pertussis vaccines].
    Locht C
    Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis.
    Mielcarek N; Riveau G; Remoué F; Antoine R; Capron A; Locht C
    Nat Biotechnol; 1998 May; 16(5):454-7. PubMed ID: 9592394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs.
    Hallander HO; Advani A; Donnelly D; Gustafsson L; Carlsson RM
    J Clin Microbiol; 2005 Jun; 43(6):2856-65. PubMed ID: 15956409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of a pertussis toxin S1 fragment by inducible promoters in oral Streptococcus and the induction of immune responses during oral colonization in mice.
    Mallaley PP; Halperin SA; Morris A; MacMillan A; Lee SF
    Can J Microbiol; 2006 May; 52(5):436-44. PubMed ID: 16699568
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of Pertussis Toxin Expression in B2 and THIJS Media.
    Moradtalab H; Noofeli M; Zeighami H; Haghi F
    Arch Razi Inst; 2019 Mar; 74(1):59-67. PubMed ID: 31013007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin.
    Bouchez V; Brun D; Cantinelli T; Dore G; Njamkepo E; Guiso N
    Vaccine; 2009 Oct; 27(43):6034-41. PubMed ID: 19666155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human T-cell immunity against Bordetella pertussis analyzed at clonal level.
    Tagliabue A; De Magistris MT; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():253-7. PubMed ID: 2908527
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence.
    Sealey KL; Belcher T; Preston A
    Infect Genet Evol; 2016 Jun; 40():136-143. PubMed ID: 26932577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening and Genomic Characterization of Filamentous Hemagglutinin-Deficient Bordetella pertussis.
    Weigand MR; Pawloski LC; Peng Y; Ju H; Burroughs M; Cassiday PK; Davis JK; DuVall M; Johnson T; Juieng P; Knipe K; Loparev VN; Mathis MH; Rowe LA; Sheth M; Williams MM; Tondella ML
    Infect Immun; 2018 Apr; 86(4):. PubMed ID: 29358336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The new strategy for allele identification of the genes coding for pertussis toxin subunit S1 (ptx S1) and pertactin (prn) in Bordetella pertussis.
    Fiett J; Letowska I; Gniadkowski M; Hryniewicz W
    J Microbiol Methods; 2003 Dec; 55(3):651-66. PubMed ID: 14607408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of real-time PCR and pyrosequencing for typing Bordetella pertussis toxin subunit 1 variants.
    Storm M; Advani A; Pettersson M; Hallander HO; Bondeson K
    J Microbiol Methods; 2006 Apr; 65(1):153-8. PubMed ID: 16095736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines.
    Markey K; Asokanathan C; Feavers I
    Toxins (Basel); 2019 Jul; 11(7):. PubMed ID: 31319496
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Towards replacement of the acellular pertussis vaccine safety test: Comparison of in vitro cytotoxic activity and in vivo activity in mice.
    Wagner LD; Corvette LJ; Ngundi MM; Burns DL
    Vaccine; 2017 Dec; 35(51):7160-7165. PubMed ID: 29122386
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012.
    van Gent M; Heuvelman CJ; van der Heide HG; Hallander HO; Advani A; Guiso N; Wirsing von Kőnig CH; Vestrheim DF; Dalby T; Fry NK; Pierard D; Detemmerman L; Zavadilova J; Fabianova K; Logan C; Habington A; Byrne M; Lutyńska A; Mosiej E; Pelaz C; Gröndahl-Yli-Hannuksela K; Barkoff AM; Mertsola J; Economopoulou A; He Q; Mooi FR
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):821-30. PubMed ID: 25527446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.